The stock is trading at $2.04 which is marginally under $2.15, the stock’s 50 day moving average and just below the 200 day moving average of $2.13. The 50 day moving average was down by -5.09% whereas the 200 day average was down by -4.25%. (NASDAQ:CATB) shares saw light trading volume with 848K shares changing hands in the last trading session. Volume was down 51.98% under the stocks average daily volume.
Short traders are feeling a little more bearish on shares of the company if you evaluate the change in short interest. The stock saw a rise in short interest between September 29, 2017 and October 13, 2017 of 280.79%. Short shares increased 449,578 over that period. Days to cover decreased 0.0 to 0.0 and the short interest percentage is 0.03% as of October 13.
A few notable investment firms have updated their holdings. Blackrock Inc. trimmed its ownership by selling 16,148 shares a decrease of 86.7% as of 06/30/2017. Blackrock Inc. currently owns 2,484 shares worth $4,000. The value of the position overall is down by 86.7%. Tower Research Capital LLC (trc) bolstered its investment by buying 126 shares an increase of 9.7%. Tower Research Capital LLC (trc) now holds 1,426 shares valued at $2,000. The total value of its holdings decreased 0.0%.
As of the end of the quarter Alyeska Investment Group, L.p. had sold 6,508 shares trimming its position 2.9%. The value of the investment in CATB decreased from $354,000 to $303,000 a change of $51,000 quarter to quarter. As of quarter end Sphera Funds Management Ltd. had disposed of a total of 100,000 shares trimming its holdings by 25.8%. The value of the investment in (CATB) went from $621,000 to $409,000 a change of 34.1% since the last quarter.
On October 5 Citigroup maintained a stock rating of “Neutral” but moved down the price target to $3.50 from $8.00.
In the latest earnings report the EPS was $-1.71 and is expected to be $-1.39 for the current year with 22,481,000 shares presently outstanding. Analysts expect next quarter’s EPS to be $-0.33 and the next full year EPS is anticipated to be $-1.10.
Catabasis Pharmaceuticals, Inc., launched on June 26, 2008, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Business’s primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Business’s CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. The Business’s CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Business’s CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA..